Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck & Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.
Merck reported a mixed second-quarter earnings picture on Tuesday. Adjusted earnings exceeded analyst consensus, but overall sales declined slightly year-over-year and fell short of revenue expectations.
